Literature DB >> 19317385

Refractory restless legs syndrome likely caused by olanzapine.

Imran Khalid1, Lopa Rana, Tabindeh J Khalid, Timothy Roehrs.   

Abstract

We report a case of severe restless legs syndrome (RLS) that occurred as a side effect of olanzapine therapy. It was refractory to treatment with 2 mg of clonazepam and 3 mg ropinirole. There was partial relief with propoxyphene, however, it was stopped because of side effects. The symptoms disappeared once olanzapine was switched to another antipsychotic medication. Only two prior published reports associate olanzapine usage with development of RLS. In one report, low-dose benzodiazepines and ropinirole were associated with resolution of RLS symptoms stating dopamine depletion as the likely etiology. In our patient, however, RLS due to olanzapine was refractory to the trial of both high-dose benzodiazepine and ropinirole. This suggests that RLS occurring as a side effect of olanzapine therapy may have additional causative mechanisms beyond simple dopamine depletion as postulated before. High-dose narcotics, if tolerated, may be an alternative in such refractory cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19317385      PMCID: PMC2637170     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  8 in total

1.  Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.

Authors:  T Kraus; A Schuld; T Pollmächer
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

2.  Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.

Authors:  G Ruaño; J W Goethe; C Caley; S Woolley; T R Holford; M Kocherla; A Windemuth; J de Leon
Journal:  Mol Psychiatry       Date:  2007-01-02       Impact factor: 15.992

Review 3.  Pathophysiological concepts of restless legs syndrome.

Authors:  Walter Paulus; Pascal Dowling; Roselyne Rijsman; Karin Stiasny-Kolster; Claudia Trenkwalder; Al de Weerd
Journal:  Mov Disord       Date:  2007-07-30       Impact factor: 10.338

4.  Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?

Authors:  Robert M Kessler
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

5.  Evaluation of selective actions of dopamine D-1 and D-2 receptor agonists and antagonists on opioid antinociception.

Authors:  K F Rooney; R D Sewell
Journal:  Eur J Pharmacol       Date:  1989-09-22       Impact factor: 4.432

Review 6.  Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?

Authors:  Walter Paulus; Eike D Schomburg
Journal:  Sleep Med Rev       Date:  2006-06       Impact factor: 11.609

7.  Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.

Authors:  Seung-Gul Kang; Heon-Jeong Lee; Leen Kim
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

8.  Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals.

Authors:  Jun-Sheng Wang; Robin Taylor; Ying Ruan; Jennifer L Donovan; John S Markowitz; C Lindsay De Vane
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

  8 in total
  7 in total

1.  Restless legs syndrome due to aripiprazole.

Authors:  Juan Bolaños-Vergaray; Juan Carlos Obaya; Rafael Gonzalez; Cristina Echeverri; Pilar Piquer
Journal:  Eur J Clin Pharmacol       Date:  2010-11-21       Impact factor: 2.953

2.  Integrating sleep management into clinical practice.

Authors:  Catherine C Schuman; Hrayr P Attarian
Journal:  J Clin Psychol Med Settings       Date:  2012-03

3.  Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS).

Authors:  Donald L Bliwise; Rebecca H Zhang; Nancy G Kutner
Journal:  Sleep Med       Date:  2014-06-13       Impact factor: 3.492

4.  Association of Restless Legs Syndrome With Incident Parkinson's Disease.

Authors:  Szabolcs Szatmari; Daniel Bereczki; Katalin Fornadi; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Miklos Z Molnar
Journal:  Sleep       Date:  2017-02-01       Impact factor: 5.849

Review 5.  Addressing sleep disturbances: an opportunity to prevent cardiometabolic disease?

Authors:  Michael A Grandner
Journal:  Int Rev Psychiatry       Date:  2014-04

Review 6.  Restless Legs Syndrome and the Use of Antipsychotic Medication: An Updated Literature Review.

Authors:  Wael K Saber; Ahad R Almuallim; Rami Algahtani
Journal:  Cureus       Date:  2022-08-09

7.  Olanzapine-induced restless leg syndrome: a case report and review of literature.

Authors:  Aniruddha Basu; Savita Kundu; Hitesh Khurana
Journal:  Indian J Pharmacol       Date:  2014 Jul-Aug       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.